Compare Abeona Therapeutics Inc (ABEO) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.81 (market cap $77.30B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 207.1× Abeona Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MDLZ | |
|---|---|---|
Market Cap | $373.32M | $77.30B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $70.75 |
52-Week Low | $4.17 | $51.51 |
Enterprise Value | $228.22M | $97.40B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MDLZ trades at $60.22, down 1.13% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 75.6% analyst buy rating. Revenue grew to $38.54B in 2025, though net margin compressed to 6.36%. Recent news highlights innovation in brands like Toblerone and Sour Patch Kids, alongside a new CFO appointment and a $0.50 dividend declaration.
Outlook: Wall Street consensus target of $67.86 suggests 12.7% upside, supported by resilient snacking demand and cost management. Risks include cocoa price volatility and competitive pressures, but the stock offers value with a P/E of 29.3 and stable cash flows, positioning it for recovery if technical resistance at $61 is breached.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
